Risk of cancer in patients treated with recombinant human growth hormone in childhood

키워드

참고문헌 (69)

1. Clayton PE, "Growth hormone, the insulin-like growth factor axis, insulin and cancer risk", Nat Rev Endocrinol, 7, pp.11~24 (2011)
2. Ranke MB, "Growth hormone - past, present and future", Nat Rev Endocrinol, 14, pp.285~300 (2018)
3. LeRoith D, "Molecular and cellular aspects of the insulin-like growth factor I receptor", Endocr Rev, 16, pp.143~163 (1995)
4. Le Roith D, "The somatomedin hypothesis: 2001", Endocr Rev, 22, pp.53~74 (2001)
5. Baker J, "Role of insulin-like growth factors in embryonic and postnatal growth", Cell, 75, pp.73~82 (1993)
6. Shimasaki S, "Identification and molecular characterization of insulin-like growth factor binding proteins (IGFBP-1, -2, -3, -4, -5 and -6)", Prog Growth Factor Res, 3, pp.243~266 (1991)
7. Cianfarani S, "Somatomedin-binding proteins:what role do they play in the growth process?", Eur J Pediatr, 149, pp.76~79 (1989)
8. Hwa V, "The insulin-like growth factor-binding protein (IGFBP) superfamily", Endocr Rev, 20, pp.761~787 (1999)
9. Baxter RC, "Circulating binding proteins for the insulinlike growth factors", Trends Endocrinol Metab, 4, pp.91~96 (1993)
10. Guler HP, "Insulin-like growth factors I and II in healthy man. Estimations of half-lives and production rates", Acta Endocrinol (Copenh), 121, pp.753~758 (1989)
11. Jones JI, "Insulin-like growth factors and their binding proteins: biological actions", Endocr Rev, 16, pp.3~34 (1995)
12. Binoux M, "Insulin-like growth factor (IGF)and IGF-binding proteins: comparison of human serum and lymph", J Clin Endocrinol Metab, 67, pp.509~514 (1988)
13. Twigg SM, "Insulin-like growth factor (IGF)-binding protein 5 forms an alternative ternary complex with IGFs and the acid-labile subunit", J Biol Chem, 273, pp.6074~6079 (1998)
14. Cianfarani S, "Do insulin-like growth factor binding proteins (IGFBPs)modulate the IGF-I growth promoting and differentiating effects in human neuroblastoma cells?", Eur J Endocrinol, 135, pp.716~723 (1996)
15. Louvi A, "Growth-promoting interaction of IGF-II with the insulin receptor during mouse embryonic development", Dev Biol, 189, pp.33~48 (1997)
16. Kornfeld S, "Structure and function of the mannose 6-phosphate", insulinlike growth factor II receptors, 1992, pp.61, 307~330
17. Kaulsay KK, "Autocrine stimulation of human mammary carcinoma cell proliferation by human growth hormone", Exp Cell Res, 250, pp.35~50 (1999)
18. Mukhina S, "Phenotypic conversion of human mammary carcinoma cells by autocrine human growth hormone", Proc Natl Acad Sci U S A, 101, pp.15166~15171 (2004)
19. Zhu T, "Oncogenic transformation of human mammary epithelial cells by autocrine human growth hormone", Cancer Res, 65, pp.317~324 (2005)
20. LeRoith D, "Insulin-like growth factors and cancer", Ann Intern Med, 122, pp.54~59 (1995)
21. Daughaday WH, "The possible autocrine", paracrine and endocrine roles of insulin-like growth factors of human tumors, 1990, pp.127, 1~4
22. Macaulay VM, "Insulin-like growth factors and cancer", Br J Cancer, 65, pp.311~320 (1992)
23. Reeve JG, "Insulin-like growth-factor-binding protein gene expression and protein production by human tumour cell lines", Int J Cancer, 51, pp.818~821 (1992)
24. Frost VJ, "Proteolytic modification of insulin-like growth factor-binding proteins: comparison of conditioned media from human cell lines, circulating proteases and characterized enzymes", J Endocrinol, 138, pp.545~554 (1993)
25. Blakesley VA, "Tumorigenic and mitogenic capacities are reduced in transfected fibroblasts expressing mutant insulin-like growth factor (IGF)-I receptors. The role of tyrosine residues 1250, 1251, and 1316 in the carboxy-terminus of the IGF-I receptor", Endocrinology, 137, pp.410~417 (1996)
26. Leventhal PS, "Insulin-like growth factors as regulators of cell motility signaling mechanisms", Trends Endocrinol Metab, 8, pp.1~6 (1997)
27. Puglianiello A, "IGF-I stimulates chemotaxis of human neuroblasts. Involvement of type 1 IGF receptor, IGF binding proteins, phosphatidylinositol-3 kinase pathway and plasmin system", J Endocrinol, 165, pp.123~131 (2000)
28. Sporn MB, "Autocrine growth factors and cancer", Nature, 313, pp.745~747 (1985)
29. Swanson SM, "The growth hormone-deficient Spontaneous Dwarf rat is resistant to chemically induced mammary carcinogenesis", Carcinogenesis, 23, pp.977~982 (2002)
30. Ramsey MM, "Growth hormone-deficient dwarf animals are resistant to dimethylbenzanthracine (DMBA)-induced mammary carcinogenesis", Endocrinology, 143, pp.4139~4142 (2002)
31. Yang XF, "Reduced growth of human breast cancer xenografts in hosts homozygous for the lit mutation", Cancer Res, 56, pp.1509~1511 (1996)
32. Tornell J, "Induction of mammary adenocarcinomas in metallothionein promoter-human growth hormone transgenic mice", Int J Cancer, 49, pp.114~117 (1991)
33. Chan JM, "Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study", Science, 279, pp.563~566 (1998)
34. Giovannucci E, "A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women", Cancer Epidemiol Biomarkers Prev, 9, pp.345~349 (2000)
35. Hankinson SE, "Circulating concentrations of insulin-like growth factor-I and risk of breast cancer", Lancet, 351, pp.1393~1396 (1998)
36. Ma J, "Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3", J Natl Cancer Inst, 91, pp.620~625 (1999)
37. Travis RC, "A meta-analysis of individual participant data reveals an association between circulating levels of IGF-I and prostate cancer risk", Cancer Res, 76, pp.2288~2300 (2016)
38. Baris D, "Acromegaly and cancer risk: a cohort study in Sweden and Denmark", Cancer Causes Control, 13, pp.395~400 (2002)
39. Kauppinen-Makelin R, "Increased cancer incidence in acromegaly--a nationwide survey", Clin Endocrinol (Oxf), 72, pp.278~279 (2010)
40. Orme SM, "Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group", J Clin Endocrinol Metab, 83, pp.2730~2734 (1998)
41. Ron E, "Acromegaly and gastrointestinal cancer", Cancer, 68, pp.1673~1677 (1991)
42. Anand A, "Acromegaly and gastrointestinal cancer", Arch Intern Med, 155, pp.213~ (1995)
43. Shevah O, "Patients with congenital deficiency of IGF-I seem protected from the development of malignancies: a preliminary report", Growth Horm IGF Res, 17, pp.54~57 (2007)
44. Steuerman R, "Congenital IGF1deficiency tends to confer protection against post-natal development of malignancies", Eur J Endocrinol, 164, pp.485~489 (2011)
45. Leslie M, "Genetics and disease. Growth defect blocks cancer and diabetes", Science, 331, pp.837~ (2011)
46. Watanabe S, "Leukemia and other malignancies among GH users", J Pediatr Endocrinol, 6, pp.99~108 (1993)
47. Bell J, "Long-term safety of recombinant human growth hormone in children", J Clin Endocrinol Metab, 95, pp.167~177 (2010)
48. Swerdlow AJ, "Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-85: a cohort study", Lancet, 360, pp.273~277 (2002)
49. van Bunderen CC, "Does growth hormone replacement therapy reduce mortality in adults with growth hormone deficiency? Data from the Dutch National Registry of Growth Hormone Treatment in adults", J Clin Endocrinol Metab, 96, pp.3151~3159 (2011)
50. Gaillard RC, "Feldt-Rasmussen U, et al. Overall and cause-specific mortality in GH-deficient adults on GH replacement", Eur J Endocrinol, 166, pp.1069~1077 (2012)
51. Carel JC, "Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature:preliminary report of the French SAGhE study", J Clin Endocrinol Metab, 97, pp.416~425 (2012)
52. Wilton P, "Growth hormone treatment in children is not associated with an increase in the incidence of cancer: experience from KIGS (Pfizer International Growth Database)", J Pediatr, 157, pp.265~270 (2010)
53. Child CJ, "Assessment of primary cancers in GH-treated adult hypopituitary patients: an analysis from the Hypopituitary Control and Complications Study", Eur J Endocrinol, 165, pp.217~223 (2011)
54. Woodmansee WW, "Incidence of second neoplasm in childhood cancer survivors treated with GH:an analysis of GeNeSIS and HypoCCS", Eur J Endocrinol, 168, pp.565~573 (2013)
55. Ergun-Longmire B, "Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor", J Clin Endocrinol Metab, 91, pp.3494~3498 (2006)
56. Mackenzie S, "Long-term safety of growth hormone replacement after CNS irradiation", J Clin Endocrinol Metab, 96, pp.2756~2761 (2011)
57. Deodati A, "Association between growth hormone therapy and mortality, cancer and cardiovascular risk: systematic review and meta-analysis", Growth Horm IGF Res, 24, pp.105~111 (2014)
58. Savendahl L, "Long-term mortality and causes of death in isolated GHD, ISS, and SGA patients treated with recombinant growth hormone during childhood in Belgium, The Netherlands, and Sweden: preliminary report of 3 countries participating in the EU SAGhE study", J Clin Endocrinol Metab, 97, pp.E213~E213 (2012)
59. Albertsson-Wikland K, "Mortality Is not increased in recombinant human growth hormone-treated patients when adjusting for birth characteristics", J Clin Endocrinol Metab, 101, pp.2149~2159 (2016)
60. Quigley CA, "Mortality in children receiving growth hormone treatment of growth disorders: data from the genetics and neuroendocrinology of short stature international study", J Clin Endocrinol Metab, 102, pp.3195~3205 (2017)
61. Child CJ, "Safety outcomes during pediatric GH therapy: final results from the prospective GeNeSIS observational program", J Clin Endocrinol Metab, 104, pp.379~389 (2019)
62. Allen DB, "GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults", Eur J Endocrinol, 174, pp.P1~P9 (2016)
63. Sklar CA, "Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study", J Clin Endocrinol Metab, 87, pp.3136~3141 (2002)
64. Patterson BC, "Growth hormone exposure as a risk factor for the development of subsequent neoplasms of the central nervous system: a report from the childhood cancer survivor study", J Clin Endocrinol Metab, 99, pp.2030~2037 (2014)
65. Swerdlow AJ, "Description of the SAGhE Cohort: a large European Study of mortality and cancer incidence risks after childhood treatment with recombinant growth hormone", Horm Res Paediatr, 84, pp.172~183 (2015)
66. Swerdlow AJ, "Cancer risks in patients treated with growth hormone in childhood: the SAGhE European Cohort Study", J Clin Endocrinol Metab, 102, pp.1661~1672 (2017)
67. Amélie Poidvin, "Increased risk of bone tumors after growth hormone treatment in childhood: A population-based cohort study in France", Cancer Medicine, 7(7), pp.3465~3473 (2018), Wiley[DOI]
68. Rosenfeld RG, "Long-term surveillance of growth hormone therapy", J Clin Endocrinol Metab, 97, pp.68~72 (2012)
69. Rosenfeld RG, "Pharmacological interventions for short stature: pros and cons", Nestle Nutr Inst Workshop Ser, 71, pp.207~217 (2013)

관련 논문AI추천